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Abstract 
Background and Significance: Although known to effectively provoke large scaled weight-loss, less is 
known regarding age- and sex-related influences on treatment outcomes of bariatric patients treated with a 
very-low calorie diet (VLCD) program. Purpose: This study retrospectively examined body composition 
and metabolic changes induced by a 12-wk proprietary VLCD treatment in obese patients while assessing 
age and sex differences. Methods: Male (n=16) and female (n=16) patients underwent 12 weeks of 
VLCD under standard medical care. Results: Older patients exhibited a greater relative loss of FFM 
compared to younger patients (p=0.004). Older patients also lost a greater proportion of total weight-loss 
as FFM (p=0.003) and lower proportion as FM (p=0.003) compared to the young group. This age-specific 
difference in weight-loss composition was driven by the older males. Conclusion: The results 
demonstrate the need for special clinical considerations for VLCD treated patients, such as older adults 
and perhaps older males specifically, who demonstrate a reduced quality of weight-loss compared to their 
younger counterpart.  
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Introduction 
 
Epidemiological findings from the National 
Health and Nutrition Examination Survey 
(NHANES 2011-2014) reported that just over 
36% of U.S. adults are currently classified as 
obese, while 16% represent incidences of severe 
cases (Ogden, Carroll, Fryar, & Flegal, 2015). 
Obesity reflects a prevalence rate far exceeding 
the threshold of 15% set by the World Health 
Organization (WHO) for epidemics needing 
intervention (Flegal, Carroll, Kit, & Ogden, 
2012). In fact, a recent comprehensive analysis 
indicated that in 2015, high body mass index 
(BMI) contributed to 4.0 million deaths globally 
(7.1% of deaths) which represents a 28% 
increase from 1990 (Collaborators, 2017). A 
high BMI also accounted for 28.6 million years 
lived with disability (3.6% of all cause of 
disability) (Collaborators, 2017). Hence, 
national health initiatives have prompted the 
urgency for effective clinical treatments to 
reconcile the global spread of obesity and 
subdue the heightened socioeconomic burdens 
directly attributable to this epidemic (Ogden et 
al., 2015).  Despite the methodological 
advancement in treatment options, such as 
surgical- or pharmacological-based approaches, 
medically supervised weight-loss programs 
incorporating hypocaloric dietary modifications 
have remained an ongoing and widely 
prescribed therapy for obesity (Tsai & Wadden, 
2005).  Amongst hypocaloric approaches, 
proprietary very low calorie diet (VLCD) 
programs (~800 kcal/day), e.g. Optifast
®
 (Nestlé 
HealthCare Nutrition), have been medically 
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prescribed as a purportedly viable option for 
high-risk patients whose body mass index (BMI) 
exceeds 30 kg/m
2
, or exhibit critical mortality 
risk,
 
or have failed to respond favorably to 
conventional and unmonitored weight-loss 
programs.   
 
VLCD prescriptions, which are based mostly on 
liquid meal replacement formulas, have been 
consistent with outcomes of revitalized health 
with significant body weight (BW) reductions 
ranging between 15-27% in obese subjects 
(Donnelly et al., 1993; Tsai & Wadden, 2005; 
Wadden & Frey, 1997; Walsh & Flynn, 1995).  
This loss in total body mass, however, cannot be 
solely accounted for by reduced adiposity, but 
also significant deficits in FFM, especially for 
the highly metabolically active skeletal muscle 
(Bryner et al., 1999; Chaston, Dixon, & O'Brien, 
2007; Donnelly, Jakicic, & Gunderson, 1991; 
Donnelly et al., 1993; Eston et al., 1992; McIver, 
Wycherley, & Clifton, 2012). A meta-analysis 
revealed a positive correlation between the loss 
of FFM and degree of energy restriction (r
2
= 
0.31, p=0.006), supporting the contention that a 
hallmark manifestation of VLCD treatment is a 
greater loss of FFM compared to less restrictive 
approaches (e.g. low calorie diet, LCD). In fact, 
a recent study showed that VLCD treated 
subjects lost a greater proportion of their weight 
as FFM compared to LCD treated subjects 
(Vink, Roumans, Arkenbosch, Mariman, & van 
Baak, 2016). Mitigating this reduction in FFM 
during intentional rapid weight-loss, as induced 
by VLCD, is of particular significance in older 
adults, in order to avoid a potential exacerbation 
of age-related loss of lean mass (sarcopenia), 
which may lead to profound debility and 
impaired quality of life. Therefore, the purpose 
of this retrospective study was to determine the 
effects of age and sex on weight-loss dynamics 
in VLCD-treated obese patients.   
 
Methods 
 
Study Design and Participants  
This study was a single-center retrospective 
analysis on 32 patients (age= 58±2 yrs) of TMH 
Bariatric Center who completed a 12-week 
medical weight-management program 
incorporating a proprietary VLCD (Optifast
®
; 
Nestlé HealthCare Nutrition; Florham Park, 
New Jersey, USA) between the years 2011 and 
2013.  Body composition, anthropometric, and 
metabolic panel data acquired during the 12-
week treatment period were analyzed 
retrospectively from medical chart reviews of 
male (n=16) and female (n=16) patients.  Time-
dependent changes in dependent variables were 
compared among gender and age cohorts.  Age 
groups were determined by patient cohorts 
above and below the median age of 57 years, i.e. 
Young= <57 yrs. (n=16) and Old= ≥57 yrs. 
(n=16).  All baseline descriptive measures are 
indicated in Table 1 for the total, sex, and age 
cohorts.  Patients included for analysis met the 
following criteria: 1) full completion of the 12-
week Optifast
®
 program, 2) BMI ≥ 30 kg/m2, 3) 
sedentary behavior (based on self-reported 
physical activity level), and 4) at least 18 years 
of age.  All data sets were numerically coded 
with no accessible link to patient information. 
This investigation was approved by the 
Institutional Review Boards of Florida State 
University and TMH.  
 
Measure and Procedures 
Dietary Treatment Program. The medical 
weight-management program of focus was 
administered at the TMH Bariatric Center and 
prescribed by a board certified bariatric 
physician. The program incorporated a 12-week 
rapid weight-loss treatment period comprised of 
full meal-replacement administered through 
liquid- and solid-based formulas, i.e. Optifast
®
. 
No other foods outside of the Optifast
®
 products 
were consumed during the treatment period. A 
standard Optifast
®
 treatment is implemented 
through a variety of products comprised of a 
powder mix, ready-to-drink blend, instant soup, 
and bars, all of which contain equivalent 
macronutrient (i.e. 35% protein, 50% 
carbohydrate, and 15% fat) and micronutrient 
composition per product, equating to 160 
kcals/product.  Participants were prescribed 5 
products a day yielding a total of 800 kcals, 70 g 
of protein, 100 g of carbohydrates, 15 g of fat, 
and 100% of the Daily Value for 24 vitamins 
and minerals. Participants were medically 
supervised and required to visit the TMH 
Bariatric Center each week on a designated time 
and day.  During each visit, participants 
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underwent anthropometric assessments and 
attended a group education class mediated by a 
registered dietician.  The bariatric physician 
monitored the participant’s progress and medical 
condition regularly throughout the treatment 
period.   
Table 1 
 
Mean Values for Descriptive Variables for Total, 
Sex, and Age Cohorts 
 
Total 
(N=32) 
Male 
(n=16) 
Female 
(n=16) 
Young 
(n=16) 
Old 
(n=16) 
Age 
(yrs) 
58.1 
(1.5) 
58.9 
(2.3) 
57.6 
(2.1) 
51.4 
(1.1)^ 
65.1 
(1.5)^ 
BW 
(kg) 
131.2 
(4.2) 
143.2 
(4.2)* 
119.1 
(6.1)* 
137.4 
(5.2) 
124.9 
(6.5) 
Height 
(cm) 
169.0 
(1.9) 
177.2 
(1.4)† 
160.8 
(2.1)† 
171.9 
(3.0) 
166.1 
(2.2) 
FM 
(kg) 
62.1 
(2.7) 
62.2 
(3.4) 
62.0 
(4.3) 
67.8 
(3.4)γ 
56.4 
(3.7)γ 
FFM 
(kg) 
69.1 
(2.9) 
81.0 
(3.2)† 
57.1 
(2.2)† 
69.6 
(3.5) 
68.5 
(4.6) 
BMI 
(kg/m2
) 
45.8 
(1.3) 
45.6 
(1.3) 
46.1 
(2.3) 
46.6 
(1.7) 
45.1 
(2.0) 
WC 
(cm) 
137.6 
(2.6) 
144.2 
(2.7)* 
131.0 
(3.8)* 
138.3 
(3.1) 
137.0 
(4.2) 
BW= body weight, FM= fat mass, FFM= fat free 
mass, BF%= body fat percentage, FFM%= fat free 
mass percentage, BMI= body mass index, WC= waist 
circumference.  Age cohorts split above and below 
median age (57yrs), i.e. Young= age < 57; Old= age 
≥57.  Values reported as mean (SE). 
different between sexes (*p<0.009), (†p<0.0001) 
different between age-groups (^p<0.0001), (γ p=0.32) 
 
Anthropometry and Body Composition. 
Anthropometric parameters and body 
composition (two-compartment model) were 
measured at the TMH Bariatric Center using an 
FDA-approved medical body composition 
analyzer (Tanita TBF-310; Arlington Heights, 
Illinois, USA) that is equipped with a BW scale 
and bioelectrical impedance analysis (BIA) 
capabilities.  The analyzer provided computed 
measurements for BW, BMI, body fat 
percentage (BF%), fat mass (FM), and lean mass 
as fat free mass (FFM) (i.e. FFM = BW - FM); 
the FFM compartment includes lean soft tissues 
plus bone mineral content. Percentage of FFM 
of total BW (FFM%) was extrapolated from BIA 
data.  Waist circumference (WC) was measured 
through a previously described protocol (Berk et 
al., 2012).  BW and BMI were recorded each 
week during the 12-week treatment period.  
Body composition and anthropometric variables, 
i.e. FM, FFM, BF%, FFM%, and WC, were 
measured once pre- and post-treatment. The 
body composition analyzer demonstrated good 
reliability with a test re-test coefficient of 
variation of 1.6%.   
 
Metabolic Panel.  Lipid panels included values 
for total cholesterol, triacylglycerol (TAG), 
high-density lipoprotein (HDL), low-density 
lipoprotein (LDL) and very low-density 
lipoprotein (VLDL).  Other metabolic tests 
included fasting blood glucose levels as well as 
hemoglobin A1c (HbA1c) values.  All measures 
were obtained in the 8-hour fasted state.  
Systemic metabolic profiles were measured pre- 
and post-treatment. 
 
Statistical Analyses 
All data are presented as mean ± standard error 
(SE).  All descriptive variables were analyzed 
using a dependent student t-test for baseline 
comparisons between sexes and between age-
groups.  Pre- and post-treatment measurements 
for body composition, anthropometric, and 
metabolic biomarkers were analyzed using a 2 
(sex) x 2 (age) x 2 (time) repeated measures 
ANOVA.  Relative change from pre- to post-
treatment for all dependent variables were 
calculated and analyzed by a 2 (sex) x 2 (age) 
multifactorial ANOVA.  In the event of a 
significant main effect or interaction, a Tukey 
post hoc test was used for pairwise comparisons.  
All statistical analyses were performed using 
Statistical Package for Social Sciences (SPSS) 
with significance set at p<0.05.  
     
Results 
Body Composition 
There was a significant change from pre- to 
post-treatment for all body composition and 
anthropometric variables when examining the 
sample in aggregate as well as in individual sex 
and age cohorts (Tables 2-4).  
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Table 2 
 
Pre- and Post-treatment Means for Anthropometric 
and Body Composition Measures for Total Sample 
 Total (N= 32) 
 Pre Post ∆ (%) 
BW 
(kg) 
131.2  
(4.2) 
109.0 (4.0) -17.2 (1.0)* 
FM 
(kg) 
62.1 (2.7) 45.5 (2.9) -27.8 (2.2)* 
FFM 
(kg) 
69.1 (2.9) 63.5 (2.6) -8.0 (0.9)* 
BMI 
(kg/m
2
) 
45.9 (1.3) 38.1 (1.3) -17.2 (1.0)* 
WC 
(cm) 
137.6 (2.6) 119.1 (2.9) -13.6 (1.0)* 
BW= body weight, FM= fat mass FFM= fat free 
mass, BMI= body mass index, WC= waist 
circumference.  ∆= mean relative change from pre- to 
post-intervention.  Values reported as mean (SE). 
* Significant pre- to post-treatment change 
(p<0.0001) 
 
 
Table 3 
 
Sex-specific Pre-and Post-intervention Means and 
Relative Change for Anthropometric 
and Body Composition Measures 
 MALE (n= 16) FEMALE (n= 16) 
 
Pre Post ∆ (%) Pre Post 
∆ 
(%) 
BW 
(kg) 
143.2 
(4.2) 
117.
7 
(3.9) 
-17.7 
(1.3)* 
119.1 
(6.1) 
100.3 
(6.5) 
-16.6 
(1.5)
* 
FM 
(kg) 
62.2 
(3.4) 
42.7 
(3.2) 
-31.4 
(3.0)* 
62.0 
(4.3) 
48.3 
(4.8) 
-24.1 
(3.0)
* 
FFM 
(kg) 
81.0 
(3.2) 
74.9 
(2.4) 
-7.0 
(1.5)* 
57.1 
(2.2) 
52.0 
(2.1) 
-9.0 
(0.8)
* 
BMI 
(kg/m2) 
45.6 
(1.3) 
37.5 
(1.2) 
-17.7 
(1.3)* 
46.1 
(2.3) 
38.8 
(2.4) 
-16.6 
(1.5)
* 
WC 
(cm) 
144.2 
(2.7) 
126.
0 
(2.9) 
-12.6 
(2.8)* 
131.0 
(3.8) 
112.2 
(4.4) 
-14.6 
(1.5)
* 
BW= body weight, FM= fat mass, FFM= fat free mass, 
BMI= body mass index, WC= waist circumference.  
∆= mean relative change from pre- to post-
intervention.  Values reported as mean (SE).    
* Significant pre- to post-treatment change (p<0.001) 
 
 
Table 4 
 
Age-specific Pre-and Post-intervention Means 
for Body Composition and Anthropometric Measures 
 Young (n= 16) Old (n= 16) 
 Pre Post ∆ (%) Pre Post ∆ (%) 
BW 
(kg) 
137.4 
(5.2) 
114.2 
(5.5) 
-17.3 
(1.5)* 
124.9 
(6.5) 
103.8 
(5.8) 
-17.1 
(1.5)* 
FM 
(kg) 
67.8 
(3.4) 
48.3 
(4.4) 
-30.2 
(3.5)* 
56.4 
(3.7) 
42.7 
(3.7)* 
-25.4 
(2.6)* 
FFM 
(kg) 
69.6 
(3.5) 
65.8 
(3.6) 
-5.7 
(1.0)*^ 
68.5 
(4.6) 
61.1 
(3.7)* 
-10.3 
(1.3)*^ 
BMI 
(kg/m2) 
46.6 
(1.7) 
38.7 
(1.8) 
-17.3 
(1.5)* 
45.1 
(2.0) 
37.6 
(2.0)* 
-17.1 
(1.5)* 
WC 
(cm) 
138.3 
(3.1) 
118.1 
(3.7) 
-14.7 
(1.4)* 
137.0 
(4.2) 
120.2 
(4.5)* 
-12.5 
(1.4)* 
BW= body weight, FM= fat mass, FFM= fat free mass, 
BMI= body mass index, WC= waist circumference.  ∆= 
mean relative change from pre- to post-intervention.  
Values reported as mean (SE).  Young= age < 57; Old= age 
≥ 57.   
* Significant pre- to post-treatment change (p<0.05) 
^ Significantly different between age-groups (p=0.004)  
 
There were no significant differences between 
sexes for the pre- to post-treatment reductions in 
BW (p=0.61), FM (p=0.10), FFM (p=0.17), BMI 
(p=0.61), or WC (p=0.31) (Table 3). The relative 
pre- to post-treatment change in BW (p=0.94), FM 
(p=0.27), WC (p=0.28), or BMI (p=0.91) was 
equivalent between age-groups (Table 4). 
However, the old-group demonstrated a greater 
relative loss in FFM than the young-group 
(p=0.004).  
There was a sex by age interaction for the relative 
pre- to post-treatment loss of (FFM (p=0.013), 
while no interaction was detected for all other 
measures (Table 5). Post hoc analysis revealed that 
older males relatively lost more FFM than younger 
males (p=0.0003). There were no differences in 
relative FFM-loss between female age cohorts 
(p=0.72). Further, younger females lost more FFM, 
relatively, than younger males (p=0.008) while, in 
the older cohort, there were no differences between 
sexes for the relative loss of FFM (p=0.39). 
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Table 5 
 
Sex by Age-group Main Effect and Interaction for Body Composition and Anthropometric Measures 
 Young (n= 16) Old (n= 16) 
 Male (n=8) Female (n=8) Male (n=8) Female (n=8) 
 Pre Post ∆ (%) Pre Post ∆ (%) Pre Post ∆ (%) Pre Post ∆ (%) 
BW 
(kg) 
146.6 
(3.9) 
120.1 
(5.3) 
-18.2* 
(2.1) 
128.2 
(8.0) 
108.3 
(8.8) 
-
16.3* 
(1.8) 
139.8 
(7.1) 
115.3 
(5.2) 
-17.2* 
(1.6) 
110.0 
(7.4) 
92.2 
(8.1) 
-
17.0* 
(2.3) 
FM  
(kg) 
66.8 
(4.2) 
42.5 
(4.8) 
-37.0* 
(4.6) 
68.8 
(5.1) 
54.2 
(6.3) 
-
23.4* 
(3.9) 
57.6 
(4.4) 
42.9 
(3.8) 
-25.9* 
(2.7) 
55.2 
(5.7) 
42.5 
(6.0) 
-
24.8* 
(4.5) 
FFM 
(kg) 
79.8 
(3.0) 
77.6 
(2.6) 
-
2.6*^† 
(0.8) 
59.4 
(3.4) 
54.1 
(2.9) 
-
8.7*^ 
(1.0) 
82.2 
(5.3) 
72.4 
(3.5) 
-
11.3*† 
(2.1) 
54.8 
(2.3) 
49.8 
(2.6) 
-9.4* 
(1.3) 
BMI 
(kg/m
2
) 
45.0 
(1.2) 
36.8 
(1.4) 
-18.3* 
(2.1) 
48.2 
(2.9) 
40.6 
(2.6) 
-
16.4* 
(1.8) 
46.2 
(2.2) 
38.2 
(1.8) 
-17.2* 
(1.6) 
44.1 
(3.2) 
37.0 
(3.4) 
-
16.9* 
(2.3) 
WC 
(cm) 
143.2 
(3.0) 
122.4 
(4.0) 
-14.5* 
(2.1) 
133.4 
(4.6) 
113.8 
(5.5) 
-
14.8* 
(2.3) 
145.3 
(4.3) 
129.7 
(3.3) 
-10.6* 
(0.6) 
128.7 
(5.6) 
110.6 
(6.5) 
-
14.4* 
(1.9) 
BW= body weight, FM= fat mass, FFM= fat free mass, BMI= body mass index, WC= waist circumference.  ∆= 
mean relative change from pre- to post-intervention.  Values reported as mean (SE).  Young= age < 57; Old= age ≥ 
57.   
* Significant pre- to post-treatment change (p<0.001) 
^ Significantly different between young males and young females (p=0.008) 
† Significantly different between young males and old males (p=0.0003) 
 
a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Relative contribution of fat free mass (FFM)- and fat mass (FM)-loss to total weight-loss in a) 
total sample, sex and age groups and b) age by sex cohorts. Values reported as mean ± SE. Approximate 
values for mean relative contributions of FFM- and FM-loss are indicated in respective bars.   
*Significantly different between age groups (p<0.005)  
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Contributions of FM- and FFM-Loss to Total 
Weight-Loss 
The proportion of total weight-loss due to 
changes in FM and FFM differed across sexes, 
age-groups (Figure 1a), and sex-age cohorts 
(Figure 1b). Specifically, the percentage of total 
weight-loss attributed to reductions in FM was 
greater for the young-group (81.4±3.7% of total 
weight-loss) compared to the old-group 
(64.8±4.1% of total weight-loss) (p=0.003). 
Also, the percentage of total weight-loss 
attributed to loss of FFM was lower for the 
young-group (18.7±3.7% of total weight-loss) 
compared to the old-group (35.0±4.1% of total 
weight-loss) (p=0.003). The proportion of 
weight-loss due to reductions in FM and FFM 
was not different between sexes. However, a sex 
by age interaction showed that the proportion of 
weight-loss due to FM-loss was greater for 
young-males (90.5±3.5% of total weight-loss) 
versus old-males (61.8±6.3% of total weight-
loss) (p=0.002) (Figure 1b).  Also, FFM-loss 
accounted for a greater proportion of total 
weight-loss in old-males (38.3±6.3% of total 
weight-loss) compared to young-males 
(9.7±3.4% of total weight-loss) (p=0.002) 
(Figure 1b). 
 
Blood Metabolic Profile 
There was a significant time effect for HbA1c, 
fasting glucose, total cholesterol, TAG, and 
VLDL.  From pre- to post-treatment, there was a 
decrease in HbA1c (-13.5±2.7%; p=0.0009), 
fasting glucose (-8.5±2.7%; p=0.01), total 
cholesterol (-8.9±2.7%; p=0.004), TAG (-
21.2±4.6%; p=0.001), and VLDL (-20.1±6.7%; 
p=0.02).  There was a sex effect for change in 
HbA1c as males demonstrated a greater decrease 
than females pre- to post-treatment (-18.0±4.3% 
vs. -7.3±1.5%; p=0.04).  There were no sex or 
age effects for pre-to-post changes in all other 
metabolic panel variables.   
    
Discussion 
 
Overall, the VLCD-based treatment program 
produced, at least in the short-term, a clinically 
meaningful weight-loss as evidenced by a 
significant reduction in adiposity and overall 
improvement in metabolic profile. The total 
weight-loss exhibited by the aggregate patient 
group corroborates outcomes of similar VLCD 
interventions previously evaluated by Walsh and 
Flynn (1995) and Wadden et al. (1992).  
Moreover, a majority of investigations reported 
that patients who successfully completed a 
comprehensive VLCD program (that included 
lifestyle modification) generally lost 15-25% of 
initial BW in 3 to 4 months (Anderson, Konz, 
Frederich, & Wood, 2001; Astrup & Rössner, 
2000; Mustajoki & Pekkarinen, 2001; Saris, 
2001; Tsai & Wadden, 2006).  The strength of 
the present findings, however, resides in the 
differential weight-loss dynamics due to age and 
sex.  A favorable outcome for most weight-loss 
prescriptions is to maximize the reduction of FM 
while preserving or improving FFM. Lowered 
basal metabolic rate, neuromuscular deficits, 
undue fatigue, poor physical function, and 
increased risk for musculoskeletal injury have 
been reported to occur as a result of diminished 
FFM, especially during advanced aging 
(Arciero, Goran, & Poehlman, 1993; Donnelly et 
al., 2009; Finer, Swan, & Mitchell, 1986; 
Nelson, Weinsier, Long, & Schutz, 1992; 
Ravussin et al., 1988; Tsai & Wadden, 2005). 
Any of these factors taken together with the 
dramatic loss of FFM would be conducive to 
impeded fat reduction, weight recidivism, and 
relapses of prior health complications (Stiegler 
& Cunliffe, 2006). Because of the clinical 
significance of decreased FFM, weight-loss 
treatments incorporating VLCD or other 
aggressive modes of dietary modifications 
remain controversial. The weight-loss 
composition with a VLCD is approximately 
75% due to FM-loss and 25% due to FFM-loss 
(Bray et al., 2012; Weinheimer, Sands, & 
Campbell, 2010) which agrees with outcomes of 
our overall patient cohort. Interestingly, our 
findings demonstrate the observed weight-loss 
composition to be significantly affected by age 
and sex, revealing the limitations and 
controversies of current VLCD programs that 
generally fail to consider these evidentially 
influential factors. 
 
Specific findings of interest include age-related 
outcomes in weight-loss composition as opposed 
to simply total BW reduction. Total absolute 
weight-loss following the 12-week treatment 
was comparable between age groups (-17.3% for 
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young and -17.1% for old), which may lead to 
misguided perceptions that VLCD treatments 
yield equivalent benefits among younger and 
older patients. However, from a body 
composition and perhaps weight-loss quality 
standpoint, our findings suggest that VLCD 
outcomes are indeed distinct between young and 
old patients. Our data show that older patients 
lose about 17% less FM and 58% more FFM 
than their younger counterparts, thereby 
offsetting any age-related differences in total 
weight-loss. As presented in Figure 1a, the 
proportion of weight-loss from FM-loss 
decreases with age while FFM-loss becomes 
increasingly contributory. These age-specific 
effects on FM- and FFM-loss indicate that 
advancing age may negatively affect the quality 
of overall weight-loss when induced by VLCD 
and perhaps other modes of severe dietary 
restriction. This of course is based on the 
contention that good weight-loss quality is 
defined as a significant reduction in FM without 
compromising FFM. Based on the observed 
divergence in weight-loss patterns between age 
groups, the matter of sarcopenia emerges as an 
important clinical issue especially considering 
the surmounting population of obese older adults 
(Goisser et al., 2015).  
 
As a critical manifestation of advanced aging 
and obesity, previous literature supports the 
presence of a condition in which obese older 
adults demonstrate a reduced FFM to BW ratio, 
poor skeletal muscle quality, impaired physical 
function, and increased systemic inflammation 
(Bollheimer et al., 2012; Roubenoff, 2004; 
Schrager et al., 2007; Thornell, 2011; Zamboni, 
Mazzali, Fantin, Rossi, & Di Francesco, 2008). 
This condition has been collectively termed 
sarcopenic-obesity, which is fundamentally the 
coexistence of age-related muscle wasting and 
excessive adiposity (Zamboni et al., 2008). 
Consequently, the proper clinical approach to 
obesity treatment for older adults becomes an 
immense challenge due to the adverse effects of 
severe caloric restriction on FFM as evidenced 
by our current findings. In other words, it may 
be reasonable to suggest that weight-loss 
therapies, such as VLCD, exacerbate the 
sarcopenic progression for older adults. Our 
results are corroborated by a systematic review 
of 52 studies that examined age-specific changes 
in BW and FFM in response to a variable period 
of energy restriction (Weinheimer et al., 2010). 
When evaluating weight-loss composition, 50% 
of their older study cohorts lost more than 25% 
of their BW as FFM. Moreover, intentional 
weight-loss, even when excess adipose tissue is 
targeted, also includes accelerated skeletal 
muscle loss which is inversely associated with 
functional capacities for autonomous living in 
older adults (S. L. Miller & Wolfe, 2008). 
Collectively, sarcopenic-obesity renders a 
complex issue for medical practitioners who 
need to prescribe an appropriate weight-loss 
treatment that moderates the health risks related 
to obesity while also preserving muscle to 
minimize the severity of sarcopenia. Based on 
our findings, these considerations appear more 
critical for older male patients who evidently 
demonstrate greater relative loss in FFM 
compared to their younger counterparts (Table 
5), ultimately manifesting in inferior weight-loss 
quality (Figure 1b). These responses are 
intriguing when considering the previous reports 
indicating the morphological and functional 
manifestations of sarcopenia to be more severe 
in men than women (Finer, 2001; Finer et al., 
1986; Finkelstein, Fiebelkorn, & Wang, 2003; 
Iannuzzi-Sucich, Prestwood, & Kenny, 2002). 
Our comprehensive evaluation of age-specific 
responses confirms the need to restructure the 
current VLCD-based programs to better 
optimize weight-loss characteristics for older 
adults due to the aforesaid issues. Our findings 
stress the importance for healthcare 
professionals to thoroughly evaluate the risks 
and benefits of VLCD prescriptions especially 
for older adults and tailor treatment programs 
accordingly. This leads us to the question of how 
VLCD systems, like Optifast
®
, can be enhanced 
through practical interventions.   
 
As others have noted, exercise continues to be a 
key component of successful dietary weight-loss 
endeavors (Arciero, Baur, Connelly, & 
Ormsbee, 2014; Arciero et al., 2006; Bryner et 
al., 1999; Johannsen et al., 2012; Longland, 
Oikawa, Mitchell, Devries, & Phillips, 2016).  
As discussed by Miller et al. (2013), exercise 
affects a wide range of physiological, 
behavioral, and psychosocial variables, which in 
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most cases are considered more positive than 
negative for the weight-loss patient. For 
instance, Villareal et al. (2011) showed a 21% 
improvement in physical performance test scores 
when energy restriction was combined with 
formal exercise training, while the absence of 
exercise resulted in only a 12% increase. Also, 
exercise training, mostly aerobic, has been 
previously scrutinized as a means of enhancing 
weight-loss composition and/or resting 
metabolic rate during dietary restriction in obese 
participants but has shown equivocal outcomes 
(Bamman et al., 2001; Donnelly, Pronk, 
Jacobsen, Pronk, & Jakicic, 1991; Fine et al., 
1999; Hammer, Barrier, Roundy, Bradford, & 
Fisher, 1989; Hill, Sparling, Shields, & Heller, 
1987; Pavlou, Steffee, Lerman, & Burrows, 
1985). Resistance training, more specifically 
systematic and periodized resistance training, 
has been less examined despite its known 
potency in promoting anabolic adaptations in 
skeletal muscle. Further, typical VLCD systems 
and treatment programs fail to integrate 
sophisticated and structured applications of 
exercise assumingly due to the limited 
availability and translation of data to properly 
guide medical practitioners. 
 
Another area of concern is the relative protein 
content of VLCD. Previous findings suggest that 
the custom protein composition of the Optifast
®
 
system is rather inadequate especially if 
combined with a resistance training intervention.  
For instance, the current study cohort at a mean 
initial BW of 131 kg would consume a VLCD 
providing only 0.5 g of protein/kg 
bodyweight/day. Thus, VLCD formulations like 
Optifast with a protein dose of 70g/day would 
fall below the RDA of 0.8 g/kg/day.  Meta-
analyses suggested that higher-protein 
consumption of approximately 1.2 g/kg/day 
promotes greater LM maintenance than diets 
lower in protein (<0.7 g/kg/day) under weight-
loss circumstances, particularly when combined 
with resistance training (Krieger, Sitren, 
Daniels, & Langkamp-Henken, 2006; 
Weinheimer et al., 2010).  In fact, Pasiakos et al. 
(2013) showed that consuming 2-3 times above 
the RDA protein intake lowers the relative 
contribution of LM-loss to the total weight 
reduced during energy restrictive periods.  
Therefore, the RDA for protein intake, and 
thereby customary Optifast
®
 protein content, 
remains insufficient for the preservation of LM, 
especially for the average 131 kg patient.  Based 
on mean BW data from the current study, in 
addition to the aforesaid protein 
recommendation (1.2 g/kg/day), approximately 
150 g of protein per day would be required for 
the maintenance of LM during a VLCD 
intervention.  In a recent study by Longland et 
al. (2016), a higher protein intake of 2.4 
g/kg/day compared to 1.2g/kg/day yielded 
superior outcomes for LM as well as FM during 
an energy deficit combined with resistance 
training. These findings along with the present 
provide excellent support for the combined 
implementation of higher protein intake and 
resistance training in VLCD or hypocaloric 
treatment programs for obesity.   
 
The most noteworthy contribution of the current 
study is that proprietary weight-loss systems can 
be evaluated and translated in a scientifically apt 
manner. We expect our report to enable both the 
patient and practitioner a better opportunity to 
assess the risk and efficacy of proprietary VLCD 
programs with information beyond what is 
commercially advertised. We also anticipate our 
current investigation to act as a model for the 
medical nutrition industry to systematically 
evaluate dietary weight-loss products through 
scientifically sound research with complete 
transparency with their findings. As in the 
pharmaceutical industry, product evaluations 
and reporting should be mandated within the 
nutrition industry to prevent falsified or 
misleading advertising, which unfortunately has 
become quite pervasive. 
 
Overall, our findings demonstrate the 
considerable need for treatment optimization as 
it pertains to the post-VLCD management of 
BW and adiposity. Given the supported health 
benefits of VLCD-induced weight-loss for the 
severely obese, it becomes an imperative goal to 
generate post-treatment conditions that would 
minimize the chance for a patient to relapse into 
unhealthy weight-gain. Patients generally regain 
40 to 50% of BW lost approximately one to two 
years post-VLCD, especially in the absence of 
follow-up care (Tsai & Wadden, 2006; Wadden, 
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Foster, Letizia, & Stunkard, 1992; Wadden & 
Frey, 1997).  Based on our current assessment of 
the 12-week Optifast
® 
program, patients 
experience a reduction in FFM, which in certain 
cohorts, i.e. old males, is presented more 
severely than others. Because the preservation of 
FFM, metabolic rate, and physical function 
plays a critical role in the long-term maintenance 
of healthy weight status, practical interventions 
(i.e. resistance training, protein modifications) 
with large potential to address these factors 
should be integrated into VLCD-based treatment 
plans. Overall, our findings from this 
investigation support the need for the clinical 
integration of structured exercise training and 
protein modifications with the purpose of 1) 
optimizing weight-loss composition as well as 
metabolic and functional outcomes; and 2) 
promoting lifestyle modifications conducive to 
healthy weight status and long-term 
management.        
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